NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has upgraded its rating on Becton Dickinson's stock to Overweight and increased its price target.

Analyst William Quirk cited increased interest in microbiology diagnostic systems and BD's position in the market in a research note explaining the upgrade. In addition, he said BD could be poised to gain market share following a recent recall by Siemens of its MicroScan microbiology testing panels in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.